< BACK World Psoriasis Day 2026: Take part in research on psoriatic arthritis risk Oct 14, 2026 Adults with psoriasis can join HPOS, and eligible participants may also take part in the iPROLEPSIS IDBV Study Psoriasis may be most visible on the skin, but its impact can go much further. Up to one in three people with psoriasis may develop psoriatic arthritis (PsA), an inflammatory disease affecting the joints and tendons. Yet it is still difficult to predict who will develop PsA – and who will not. The HIPPOCRATES Prospective Observational Study (HPOS) is working to change that by following people with psoriasis over three years and looking for early signs linked to the development of PsA. Conducted entirely online, with no hospital visits required, the study enables people in participating countries across Europe to contribute their experiences from home. This World Psoriasis Day focuses on young people living with psoriasis under the campaign slogan #LookBeyondMySkin . By investigating what happens before PsA develops, HPOS aims to improve our understanding of the disease and, ultimately, the outlook for future generations. Join HPOS and help shape what comes next HPOS is open to adults living in participating European countries who have psoriasis and have not been diagnosed with psoriatic arthritis. Taking part is flexible and designed to fit around participants’ everyday lives. Find out if you are eligible and register: https://hpos.study/ Connecting HPOS with iPROLEPSIS HPOS participants who meet the eligibility criteria may also be able to take part in the iPROLEPSIS Inflammation Digital Biomarkers Validation (IDBV) Study . The study is exploring whether information from a smartphone could help researchers detect early changes linked to psoriatic arthritis. Participants who join the IDBV Study use the miPROLEPSIS Lite app on their smartphone for up to 12 months. Designed to fit into real life, the app collects most of the information needed for the study automatically, so there is very little for participants to do. Researchers want to understand whether changes in movement, activity and symptoms can be detected earlier using digital information collected through the study app. Learn more about the iPROLEPSIS IDBV Study and miPROLEPSIS Lite: https://www.iprolepsis.eu/idbv iPROLEPSIS_World Psoriasis Day 2026.png iPROLEPSIS_World Psoriasis Day 2026.png 1/1 PREVIOUS NEXT

The iPROLEPSIS project is where psoriatic arthritis inflammation is explained through multi-source data analysis guiding a novel personalized digital care ecosystem. iPROLEPSIS is a s olution for psoriatic arthritis The iPROLEPSIS project is where psoriatic arthritis inflammation is explained through multi-source data analysis guiding a novel personalised digital care ecosystem. LEARNING HUB PROJECT NEWS Psoriatic Arthritis (PsA) is a chronic progressive inflammatory disease affecting 1-2% of the general population, while manifesting in up to 30% of people with psoriasis (PsO). Project vision and impact iPROLEPSIS is a Horizon Europe-funded project developing a novel personalised digital care ecosystem for people with PsA. The goal of iPROLEPSIS is to propose a novel ecosystem that involves Real World Data (RWD) collection mechanisms and a powerful decision support system to provide new knowledge for the key actionable factors that affect the health-to-PsA transition, adopting a multiscale/ multifactorial approach, so, with the use of xAI-based models, to offer an efficient, effective, and clinically validated personalised digital care ecosystem for PsA patients. DISCOVER MORE Project objectives and work packages iPROLEPSIS consortium works on 7 ambitious key objectives in the field of Psoriatic Arthritis (PsA) and has 6 Work Packages of the project that will bring together various and complementary expertise from consortium partners. DISCOVER MORE About project 15 Partners 9 Countries 48 m Project duration € 6,4M Total budget The core activity domains Establishment • The foundation for the project’s research activities is laid by means of an extensive exploration of the available literature and data and the design of the clinical data collection and validation studies; • Participatory design supporting the development of a user-oriented ecosystem of solutions will be employed to establish a framework for trustworthy AI-based R&D. Validation • The design and implementation of the clinical studies that will collect research data, validate the inflammatory symptoms digital biomarkers in individuals at risk of PsA and PSO patients, and evaluate the efficacy of the digital care tools with respect to prevention of inflammation exacerbation. Research and development • Research on multimodal data to reveal key PsA inflammation drivers, provide digital biomarkers of PsA inflammatory symptoms, and explore the effect of PsA on the joints and skin microvasculature, as well as the role of mast cells in PsA transition; • Synthesise the outcomes into a multiscale/multifactorial model of the health-to-PsA transition; • Deliver the integrated iPROLEPSIS digital health ecosystem comprising tools for personalised preventive PsA care, to empower patients and HCPs. Learning Hub Explore resources to help you understand and manage psoriatic arthritis. Handbook Handbook 2 Psoriatic Arthritis Key Facts Key Facts Psoriatic Arthritis Handbook Handbook Quizzes about Psoriatic Arthritis Take a Quiz Project news Handbook Handbook 2 World Psoriasis Day 2026: Take part in research on psoriatic arthritis risk Read More Psoriatic arthritis digital phenotyping and inflammation drivers (PDPID) study Read More Understanding inflammation drivers in psoriatic arthritis Read More DISCOVER MORE Contact us We welcome your comments or questions about iPROLEPSIS project! CONTACT US

iPROLEPSIS project news Oct 14, 2026 World Psoriasis Day 2026: Take part in research on psoriatic arthritis risk Adults with psoriasis can join HPOS, and eligible participants may also take part in the iPROLEPSIS IDBV Study READ MORE Sep 15, 2026 User research and co-creation in iPROLEPSIS How patients and healthcare professionals helped shape the iPROLEPSIS Digital Care Ecosystem READ MORE Aug 26, 2026 iPROLEPSIS at IEEE EMBC 2026 Representing iPROLEPSIS at an international biomedical engineering conference READ MORE Aug 18, 2026 iPROLEPSIS at SportEx during ECSS 2026 Connecting iPROLEPSIS with the sport science community READ MORE Jun 26, 2026 iPROLEPSIS presented at DSAI 2026 Digital biomarkers, serious games and AI-supported health monitoring READ MORE May 27, 2026 iPROLEPSIS at the Aristotle Innovation Forum 2026 Showcasing digital health tools for psoriatic arthritis care READ MORE Apr 22, 2026 iPROLEPSIS presented at TeraMed Conference 2026 in Angola The project and the iPROLEPSIS Games were presented, highlighting their relevance for digital health innovation READ MORE Oct 5, 2026 Psoriatic arthritis digital phenotyping and inflammation drivers (PDPID) study New iPROLEPSIS publication presents the protocol for an international study combining clinical, biological, environmental and digital data to investigate PsA flares READ MORE Sep 8, 2026 Psoriatic Arthritis: State of the Art and Datasets A literature review of PsA symptoms, flare-related factors, monitoring approaches, predictive models and relevant datasets READ MORE Aug 24, 2026 The Spy and Zen Forest Exergames as Sources of Digital Biomarkers for Psoriatic Arthritis: A Co-Design Paradigm New iPROLEPSIS publication presents co-designed exergames to support therapeutic engagement in psoriatic arthritis READ MORE Jul 22, 2026 iPROLEPSIS Newsletter No. 12 Latest news from iPROLEPSIS READ MORE Jun 15, 2026 iPROLEPSIS Research Presented at the 60th ESCI Annual Scientific Meeting From Sensors to Predictive Algorithms: Real-World Digital Biomarkers of Disease Activity in Psoriatic Arthritis READ MORE May 18, 2026 Transforming Psoriatic Disease Care Through Innovation and Real-World Data: GRAPPA 2025 Soapbox Highlights The article highlights how iPROLEPSIS uses digital tools, smartphone-based data and explainable AI to support personalised psoriatic arthritis monitoring READ MORE Apr 1, 2026 iPROLEPSIS at Healthcare & Medical Equipment Korea 2026 Presenting iPROLEPSIS at Korea’s leading medical technology exhibition READ MORE Oct 1, 2026 Understanding inflammation drivers in psoriatic arthritis iPROLEPSIS investigates drivers of inflammation and factors associated with disease activity in psoriatic arthritis READ MORE Sep 1, 2026 Dynamic Difficulty Adjustment in Psoriatic Arthritis Serious Games Using Learning-Driven Policies New iPROLEPSIS publication presents machine learning approach to personalise game difficulty based on patient condition READ MORE Aug 21, 2026 iPROLEPSIS launches IDBV Study Inflammation Digital Biomarkers Validation study begins recruitment on 20 August 2026 READ MORE Jul 21, 2026 iPROLEPSIS Games Presented at Centro Neurológico de Torres Vedras The visit offered an opportunity to present the iPROLEPSIS Games and discuss the project’s work with the centre’s team READ MORE Jun 10, 2026 iPROLEPSIS 8th Plenary Meeting in Athens Partners met to review progress and align on next steps READ MORE Apr 23, 2026 iPROLEPSIS presented at the European OHDSI Symposium 2026 A poster presented in Rotterdam highlighted cross-country harmonization of psoriatic arthritis cohorts into the OMOP Common Data Model READ MORE 1 2 3 ... 7 1 ... 1 2 3 4 5 6 7 ... 7

< BACK Psoriatic arthritis digital phenotyping and inflammation drivers (PDPID) study Oct 5, 2026 New iPROLEPSIS publication presents the protocol for an international study combining clinical, biological, environmental and digital data to investigate PsA flares A new peer-reviewed publication from the iPROLEPSIS project presents the protocol of the Psoriatic Arthritis Digital Phenotyping and Inflammation Drivers (PDPID) study , an international multicentre prospective cohort study focused on improving the monitoring and prediction of psoriatic arthritis (PsA) flares. The study is being conducted across 30 sites in the Netherlands, United Kingdom, Portugal and Greece and follows participants with PsA for 12 months. Its main objectives are to develop and internally validate digital biomarkers capable of detecting disease flares and to develop machine-learning models for flare prediction. The PDPID study brings together several types of information. Clinical assessments and patient-reported outcomes are combined with biological markers, including DNA, gut microbiome, cortisol and C-reactive protein, as well as environmental information such as weather and air pollution. Digital data are collected through the miPROLEPSIS app and a smartwatch. These include smartphone and smartwatch sensor data, keystroke dynamics, screen time, physical activity, sleep and other wellness measures. Participants can also report flares through the app and complete questionnaires and photo- and video-based assessments. By combining these different data sources, the study aims to identify patterns associated with changes in disease activity and investigate factors that may contribute to PsA flares. The resulting models are intended to support continuous and less burdensome monitoring of disease activity and, in the longer term, contribute to more personalised approaches to PsA management. The study also incorporates patient involvement. People with PsA contributed to the development and testing of the app and continue to provide feedback on the study procedures, usability and user experience. The article, “Psoriatic arthritis digital phenotyping and inflammation drivers (PDPID) study: protocol for an international multicentre prospective cohort”, was published in BMJ Open in September 2026. Read the full open-access publication: https://doi.org/10.1136/bmjopen-2025-115903 iPROLEPSIS_PDPID protocol.png iPROLEPSIS_PDPID protocol.png 1/1 PREVIOUS NEXT

Read publications about iProlepsis project for psoriatic arthritis. Discover insights and project progress. iPROLEPSIS project publications Psoriatic arthritis digital phenotyping and inflammation drivers (PDPID) study: protocol for an international multicentre prospective cohort September 28, 2026 Changes in psoriatic arthritis (PsA) disease activity, particularly flares, are unpredictable and can impact patients’ quality of life. Digital biomarkers derived from data collected via smart devices provide an opportunity for unobtrusive continuous monitoring of symptoms reflecting disease activity. Besides, our understanding of the mechanisms and triggers behind flares is limited. The primary objectives of the Psoriatic Arthritis Digital Phenotyping and Inflammation Drivers (PDPID) study are: (1) to develop digital biomarker capable of detecting PsA flare using data collected from patient’s smartphone and smartwatch, and (2) to develop machine learning models for PsA flare prediction using clinical, biological, environmental and digital data. Read More Transforming Psoriatic Disease Care Through Innovation and Real-World Data: GRAPPA 2025 Soapbox Highlights May 15, 2026 The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2025 annual meeting, held in Bogotá, Colombia, featured soapbox presentations highlighting innovative approaches to psoriatic disease (PsD) care. Dr. Vasileios Charisis presented the Psoriatic Arthritis Inflammation Explained Through Multi-Source Data Analysis Guiding a Novel Personalised Digital Care Ecosystem (iPROLEPSIS) project, which applies digital phenotyping and explainable artificial intelligence to monitor psoriatic arthritis (PsA) using smartphone-based typing dynamics and hand motion tracking. Pilot data demonstrated high accuracy in detecting functional impairments, underscoring the potential of digital biomarkers for personalized disease management. Read More Co-Designing Mobile Serious Games to Support Patients With Psoriatic Arthritis and Chronic Pain: Mixed Methods Study February 3, 2026 This study aimed to co-design mobile serious games—NoPain Games—to support patients with PsA in managing chronic pain. Conducted within the iPROLEPSIS Horizon Europe project, the study involved a multidisciplinary cocreation session with rheumatologists, researchers, and technical experts, followed by a usability feedback session with patients with PsA. The goal was to identify therapeutic priorities, refine game mechanics, and assess usability to inform the development of personalized, accessible digital interventions. Read More Digital biomarkers for psoriatic arthritis: a qualitative focus group study on patient-perceived opportunities and barriers October 30, 2024 The widespread adoption of wearables, for example, smartphones and smartwatches in the daily lives of the general population, allows passive monitoring of physiological and behavioural data in the real world. This qualitative study explores the perspective of psoriatic arthritis (PsA) patients towards these so-called digital biomarkers (dBMs). Read More Dynamic Difficulty Adjustment in Psoriatic Arthritis Serious Games Using Learning-Driven Policies August 21, 2026 Serious Games (SGs) must sustain engagement by matching challenge to players’ abilities. Yet, fixed difficulty disregards performance or psychophysiological fluctuations. In Psoriatic Arthritis (PsA), these fluctuations are reflections of variable pain, mobility limitations, and stress. Here, we propose a Dynamic Difficulty Adjustment (DDA) that learns personalized difficulty selection responsive to PsA-related physical and emotional changes. Read More Modeling Interphalangeal Joints for Swelling Assessment in Psoriatic Arthritis via Smartphone Photographs February 4, 2026 Digital assessment of swollen joints from smartphone photographs can support remote monitoring of patients with inflammatory arthritis, enabling more efficient care delivery. In this study, we propose a method to classify each interphalangeal joint in hand photographs as swollen or not. Read More European advances in digital rheumatology: explainable insights and personalized digital health tools for psoriatic arthritis May 19, 2025 The shift from traditional to technology-based diagnosis and management of psoriatic arthritis (PsA) represents a significant evolution in patient care. Traditionally, PsA was diagnosed and managed through clinical evaluations, physical examinations, and basic imaging techniques. With the evolution of digital technologies, the PsA care is transforming, giving rise to the field of digital rheumatology. In this vein, Europe has invested in research initiatives, like iPROLEPSIS, that could accelerate this transformation and redefine PsA care within a digital world. In this Viewpoint we present the current clinical PsA landscape, highlight the PsA patients' interaction with the digital world, and showcase the novel iPROLEPSIS digital offerings. The latter scaffold digital rheumatology by identifying PsA key drivers. Moreover, they support personalized PsA risk prediction and improve early PsA detection. Furthermore, they enable precise PsA treatment strategies and digital therapeutics within a novel digital health ecosystem. Read More Developing Sensorimotor Art Games for Psoriatic Arthritis using Agile Storyboarding and Game Co-Design Processes June 28, 2024 Serious Games (SGs) have the potential to provide clinical care and enhance patients’ quality of life, while incorporating an element of entertainment. As part of the iPROLEPSIS Horizon Europe project, we introduce two Sensorimotor Art games designed as SGs to assist Psoriatic Arthritis (PsA) patients in managing their symptoms. Read More The Spy and Zen Forest Exergames as Sources of Digital Biomarkers for Psoriatic Arthritis: A Co-Design Paradigm June 5, 2026 Psoriatic Arthritis (PsA) is a chronic rheumatic condition characterized by joint stiffness, reduced mobility, and persistent pain. Alongside pharmacological treatments, physio-therapy and structured exercise are commonly prescribed to improve range of motion and physical function. However, a prevalence of low consistency, high costs, and lack of engagement leads to high drop-out rates, making these interventions ineffective. Exergames, short for exercise games, provide an accessible alternative to complement traditional interventions, which embed therapeutic movements into game mechanics, motivating patients to remain active and consistent in their rehabilitation routines. This work presents the design of two PsA-focused exergames, The Spy and Zen Forest. Both were co-designed with 29 stakeholders, including PsA patients, clinicians, researchers, and technical experts, ensuring that they align with clinical goals, address patient needs, and support safe and effective physical engagement. Read More Designing Exergames for Psoriatic Arthritis: The Spy and Zen Forest Paradigms February 4, 2026 In addition to biological interventions, traditional treatments often include physiotherapy and exercise to improve range of motion and physical function. However, a prevalence of low consistency, high costs, and lack of engagement leads to high drop-out rates, making these interventions ineffective. Exergames, short for exercise games, provide an accessible alternative to complement traditional interventions, which embed therapeutic movements into game mechanics, motivating patients to remain active and consistent in their rehabilitation routines. Here we present the design of two exergames for PsA, namely The Spy and Zen Forest. Read More Hot topic debate: preventing psoriatic arthritis in patients with psoriasis November 11, 2024 Can effective treatment of psoriasis (PsO) prevent the development of psoriatic arthritis (PsA)? In a Hot Topic Debate at the 7th World Psoriasis & Psoriatic Arthritis Conference, Dr. Soriano and Dr. Ogdie, both experts in the field, presented contrasting views based on existing research and clinical studies.1 Dr. Soriano argued that biologic treatments for PsO may reduce PsA risk, citing several retrospective studies. On the other hand, Dr. Ogdie argued that current observational data are plagued by biases, making it difficult to conclude whether biologics play a protective role. The session outlined the complexity of this issue, with both speakers agreeing on the need for prospective randomised controlled trials, such as the ongoing PAMPA study, to provide definitive answers. Prof. Laura Coates added that identifying at-risk patients and intervening early to potentially prevent PsA may point to a strategic research approach to address these unanswered questions. Read More “The Kite” Breathing Serious Game: Agile Co-Design for Psoriatic Arthritis June 27, 2024 Serious Games (SGs) have been explored in healthcare for their potential as gamified means for disease assessment and/or intervention. Designing effective SGs requires attention to user requirements and iterative development. We introduce a SG design process for Psoriatic Arthritis (PsA) patients, aiming to enhance their quality of life. Read More

< BACK Understanding inflammation drivers in psoriatic arthritis Oct 1, 2026 iPROLEPSIS investigates drivers of inflammation and factors associated with disease activity in psoriatic arthritis Psoriatic arthritis (PsA) is a chronic inflammatory disease associated with psoriasis. Patients with PsA can experience periods of increased disease activity, known as flares, but knowledge about the triggers of these flares remains limited. Within iPROLEPSIS, research is being conducted to identify key drivers of inflammation in PsA through the analysis of retrospective datasets and prospective data from the Psoriatic Disease Patient Inflammation Drivers (PDPID) study . Analysis of the DEPAR and Reuma.pt cohorts showed differences in disease activity, disease duration, phenotype and treatment. Differences between males and females were also observed across several PsA-related measures. The analysis further showed that early PsA diagnosis was associated with lower disease activity and better quality-of-life measures, while diagnosis timing alone did not determine treatment trajectory. Preliminary analysis of PDPID baseline data from the Netherlands, UK and Greece found that flare was associated with higher pain, fatigue, sleep disturbance and stiffness. Higher perceived stress was associated with higher disease activity. Higher nitrogen dioxide (NO₂) exposure was associated with higher disease activity, while higher ozone (O₃) exposure was associated with lower disease activity. The analysis will be expanded with more participants, follow-up data and additional clinical, biological and environmental data, including genetic and gut microbiome data. Read the full report on Zenodo: https://zenodo.org/records/22655513 iPROLEPSIS_D3.1.png iPROLEPSIS_D3.1.png 1/1 PREVIOUS NEXT

Download iProlepsis project applications for psoriatic arthritis. Apps for download miPROLEPSIS app The miPROLEPSIS app facilitates the iPROLEPSIS-PDPID multicenter clinical study as a data collection tool that will enable the development of digital biomarkers for psoriatic arthritis symptoms and predictive models for inflammation exacerbation. More specifically, the app performs (i) passive data collection from the sensors of the smartwatch used in the study (i.e., Garmin Vivoactive 5), (ii) passive data collection from the accelerometer and gyroscope sensors of the smartphone, (iii) patient reported outcomes via questionnaires. Moreover, the app includes (i) a custom keyboard that captures the user’s typing dynamics and (ii) photo- and video-based activities for the collection of hand/feet photos and skeletal data related to joints flexibility, respectively. Note: The app can be used only by psoriatic arthritis patients that have enrolled to the PDPID study. This enrollment is available for patients in the UK, Netherlands, Portugal, and Greece. Information on how to enroll in the study and gain access to the miPROLEPSIS app will be provided soon. miPROLEPSIS app The miPROLEPSIS PDPID Study application functions as a data collection tool, utilized during the PDPID study, in order to produce datasets used for model generation and training. The app utilises both continuous and unobtrusive data collection (via bluetooth) from wearable devices, as well as user interactions (questionnaires, reporting etc). miPROLEPSIS Joint Landmarker app The miPROLEPSIS Joint Landmarker is an accompanying app of the miPROLEPSIS app that enables the video-based active tests feature. More specifically, a set of 6 hand and body movement exercises are presented and the user is asked to perform them in front of the smartphone camera. The app captures the videos and extracts skeletal data (coordinates of skeletal joints) locally. The skeletal data will be further analysed to develop digital biomarkers that assess the functionality and flexibility of joints. Note: The miPROLEPSIS Joint Landmarker app cannot be used without the miPROLEPSIS app. miPROLEPSIS Joint Landmarker app This app is a research app that accompanies the miPROLEPSIS app and aims to assess the physical functioning of people with Psoriatic Arthritis. More specifically, a set of 6 hand and body exercises are given and the user is asked to perform them in front of the smartphone camera. The app uses the collected videos to extract skeletal data (coordinates of skeletal joints), which are then sent to a cloud for further processing. Through the skeletal data processing, the aim is to identify whether a patient with Psoriatic Arthritis have difficulties in performing certain hand and body actions. The videos are immediately discarded and no personal information is retained, saved or transmitted. miPROLEPSIS Lite app miPROLEPSIS Lite is the official companion app for participants enrolled in the miPROLEPSIS research study , which monitors joint health (e.g. psoriatic arthritis). Note: This app is intended exclusively for enrolled study participants, who receive personal login credentials from the research team. It is not intended for the general public and does not provide diagnosis or treatment. miPROLEPSIS Lite app What the app does: • Syncs health data from your connected smartwatch/wearable device • Collects phone sensor data in the background, with your consent, for the study • Guides you through short questionnaires about your symptoms • Lets you report a flare-up / joint pain at any time • Captures hand/foot photos when requested, to monitor joint condition • Records short movement video tests when requested • Lets you log your sleep hours • Notifies you when a new questionnaire or test becomes available Privacy & data: All data collected through the app is used exclusively for the purposes of the research study, in line with the consent and participation terms you received from the research team. Languages: English, Greek, Dutch, Portuguese. If you are enrolled in the miPROLEPSIS study and have not received login credentials, please contact your research team.

Download needed promo materials for iProlepsis project for psoriatic arthritis, such as posters, flyers, logos, and color palete. Promo materials to download 01 iPROLEPSIS Poster (A0) 02 iPROLEPSIS Flyer (A5) 03 iPROLEPSIS Roll-Up Poster Logo and color palette to download PNG, transparent background SVG, transparent background SVG, transparent background #212178 #B380FF #FFAACC #37C8AB #DEEBF7 PNG, white background WEBP, transparent background

iPROLEPSIS project newsletter Jul 21, 2026 Issue No. 12 iPROLEPSIS project newsletter No 12 Welcome! This is the 12th edition of the iPROLEPSIS newsletter, where we share the latest updates and progress from the project. READ THE NEWSLETTER Mar 10, 2026 Issue No. 11 iPROLEPSIS project newsletter No 11 Welcome! This is the 11th edition of the iPROLEPSIS newsletter, where we share the latest updates and progress from the project. READ THE NEWSLETTER Nov 6, 2025 Issue No. 10 iPROLEPSIS project newsletter No 10 Welcome! This is the 10th edition of the iPROLEPSIS newsletter, where we share the latest updates and progress from the project. READ THE NEWSLETTER Jul 1, 2025 Issue No. 9 iPROLEPSIS project newsletter No 9 Welcome! This is the 9th edition of the iPROLEPSIS newsletter, where we share the latest updates and progress from the project. READ THE NEWSLETTER Apr 28, 2025 Issue No. 8 iPROLEPSIS project newsletter No 8 Welcome! This is the 8th edition of the iPROLEPSIS newsletter, where we share the latest updates and progress from the project. READ THE NEWSLETTER Jan 28, 2025 Issue No. 7 iPROLEPSIS project newsletter No 7 Welcome! This is the 7th edition of the Newsletter series of the iPROLEPSIS project. In this issue, we highlight the insights on the future of digital biomarkers in rheumatology care, offer key information about PsA and practical advice to improve daily life, update about past events. READ THE NEWSLETTER Oct 9, 2024 Issue No. 6 iPROLEPSIS project newsletter No 6 Welcome! This is the 6th edition of the Newsletter series of the iPROLEPSIS project. In this issue, we highlight the release of the miPROLEPSIS and miPROLEPSIS Joint Landmarker apps, recent publications, reflections on Psoriatic Arthritis Awareness Day and Psoriasis Awareness Month, and key takeaways from recent events. READ THE NEWSLETTER Jul 9, 2024 Issue No. 5 iPROLEPSIS project newsletter No 5 Welcome! This is the 5th edition of the Newsletter series of the iPROLEPSIS project. In this newsletter issue, we delve into the updates and progress of the project activities, synergies and events. READ THE NEWSLETTER Mar 7, 2024 Issue No. 4 iPROLEPSIS project newsletter No 4 Welcome! This is the 4th edition of the Newsletter series of the iPROLEPSIS project. Let's explore the latest developments and advancements in our project activities, collaborations, and upcoming events. READ THE NEWSLETTER Nov 30, 2023 Issue No. 3 iPROLEPSIS project newsletter No 3 Welcome! This is the 3rd edition of the Newsletter series of the iPROLEPSIS project. In this newsletter issue, we delve into the updates and progress of the project activities, synergies and events. READ THE NEWSLETTER Sep 5, 2023 Issue No. 2 iPROLEPSIS project newsletter No 2 Welcome! This is the 2nd edition of the Newsletter series of the iPROLEPSIS project. In this newsletter issue, we delve into the transformative power of user research and co-creation in the healthcare innovation research process. READ THE NEWSLETTER Jul 4, 2023 Issue No. 1 iPROLEPSIS project newsletter No 1 Welcome! This is the 1st edition of the newsletter series of the iPROLEPSIS project! The 1st newsletter informs you about the iPROLEPSIS project, its vision, pillars and objectives, and the partners involved. READ THE NEWSLETTER

We welcome your comments or questions about iPROLEPSIS project!​ Feel free to contact us by filling in the form to submit your comments or questions.​ Project coordinator Prof. Leontios Hadjileontiadis Project Coordinator Aristotle University of Thessaloniki Contact us We welcome your comments or questions about iPROLEPSIS! Please contact us by filling in the form below to submit your comments or questions. Ask your question or write a comment First name Last name Email Write a message I have read and agree to the Privacy policy SUBMIT Thanks for submitting! Please note that we will not give you medical advice. To discuss symptoms or conditions, please contact your physician or other health care provider.

< BACK Exploring the iPROLEPSIS Project: Insights from J. Luime Sep 17, 2024 Innovative Approaches to Monitoring and Managing Psoriatic Arthritis Jolanda Luime, senior researcher and project partner from Erasmus MC (the Netherlands), shares insights on the iPROLEPSIS project. The iPROLEPSIS project represents a significant advancement in the field of psoriatic arthritis research. By leveraging cutting-edge technology, including smartphones and data analysis, iPROLEPSIS aims to transform how we measure and understand psoriatic arthritis activity. Traditional methods of tracking psoriatic arthritis often fall short in capturing the full scope of the disease’s impact. iPROLEPSIS seeks to address this gap by exploring new and innovative approaches. The project uses advanced technology to monitor movement patterns and other key indicators of disease activity, offering a more comprehensive view of how the condition affects patients on a daily basis. One of the core objectives of iPROLEPSIS is to empower patients with better tools for managing their condition. By providing more detailed insights into disease activity, the project aims to help patients make informed decisions about their health and potentially prevent disease flares before they occur. This proactive approach has the potential to significantly improve the quality of life for those living with psoriatic arthritis. In addition to benefiting patients, iPROLEPSIS aims to to support clinicians by offering more accurate and actionable data. With better insights into disease activity and treatment effectiveness, healthcare providers can make more informed decisions regarding medication adjustments and overall treatment strategies. This not only enhances patient care but also helps streamline clinical practices, making the process more efficient and effective. Through the iPROLEPSIS project, the aim is to provide patients and clinicians with the tools they need to better understand and manage psoriatic arthritis, ultimately improving both patient outcomes and clinical practices. https://www.youtube.com/watch?v=G2Gz-gl5uBY 1/1 PREVIOUS NEXT

< BACK Highlights from IEEE EMBS 2024 Sep 5, 2024 Showcasing AI-Based Solutions for Psoriatic Arthritis Care Our project partner, PLUX Biosignals, participated in the 46th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBS) , held in Orlando, Florida, USA, from July 15-19, 2024. During this prestigious event, PLUX presented the innovative work of the iPROLEPSIS project, which focuses on developing a novel, personalised digital care ecosystem for individuals with psoriatic arthritis. The world's largest international biomedical engineering conference, IEEE EMBS 2024 featured an extensive range of scientific tracks covering cutting-edge research and innovations in biomedical engineering and healthcare technology. Topics included women and children's health, translational clinical research, technology transfer, entrepreneurship, and biomedical engineering education. This event provided a valuable platform for showcasing the potential of AI-based solutions in improving care for psoriatic arthritis patients and highlighted the role of digital tools in revolutionizing personalised healthcare. 1/2 PREVIOUS NEXT